Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2017-11-06 Board/Management Inform…
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the departure of a director, amendments to the certificate of incorporation and bylaws, and the completion of an initial public offering (IPO). These are typical disclosures for a Form 8-K. The document does not contain financial statements or detailed financial analysis, so it is not an Annual Report (10-K) or Interim Report (IR). It also does not fit into categories like Earnings Release or Management Reports. The primary focus is on management changes and corporate governance amendments, which aligns with Board/Management Information (MANG). Therefore, the best classification is MANG with high confidence.
2017-11-06 English
Regulatory Filings 2017
Regulatory Filings
2017-11-06 English
424B4
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus for an initial public offering (IPO) of common stock by Spero Therapeutics, Inc. It includes information about the offering size, price, underwriting, risk factors, use of proceeds, dividend policy, capitalization, dilution, financial data, management discussion and analysis, business overview, management, executive compensation, stockholders, and legal matters. The document is a registration statement filed pursuant to Rule 424(b)(4), which is a prospectus supplement related to securities offerings. This type of document is a capital markets filing related to fundraising and issuance of new shares to the public. It is not an annual or quarterly report, audit report, earnings release, or any other type of corporate report. It is specifically a prospectus for a public offering of shares, which falls under the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms and company information relevant to investors in the context of a capital raise.
2017-11-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2017-11-02 English
Regulatory Filings 2017
Regulatory Filings
2017-11-02 English
FORM 3 SUBMISSION
Director's Dealing
2017-11-01 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.